Brooks Laboratories Limited (IN:BROOKS)
:BROOKS
Want to see IN:BROOKS full AI Analyst Report?
Top Page
Brooks Laboratories Limited
(BROOKS)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹59.00
▼(-52.28% Downside)
Action:ReiteratedDate:04/08/26
The score is held back mainly by weak financial performance—especially persistent net losses and negative operating/free cash flow—despite some balance-sheet improvement. Technicals are mixed (short-term strength but weak longer-term trend and negative MACD). Valuation is a partial offset due to a modest P/E.
Positive Factors
Improving Leverage
A declining debt load and stable equity ratio reduce solvency risk and improve financial flexibility over the medium term. This creates capacity for targeted reinvestment or opportunistic financing on better terms, lowering bankruptcy risk and supporting longer-term strategic initiatives.
Negative Factors
Persistent Negative Cash Flow
Multi-year operating cash deficits indicate structural cash burn that undermines long-term viability if unmet by consistent operational improvement or external funding. Persistent negative FCF constrains capex, R&D, and working capital, forcing reliance on financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Leverage
A declining debt load and stable equity ratio reduce solvency risk and improve financial flexibility over the medium term. This creates capacity for targeted reinvestment or opportunistic financing on better terms, lowering bankruptcy risk and supporting longer-term strategic initiatives.
Read all positive factors
Brooks Laboratories Limited (BROOKS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.75B
Dividend YieldN/A
Average Volume (3M)2.20K
Price to Earnings (P/E)10.7
Beta (1Y)1.62
Revenue Growth15.44%
EPS GrowthN/A
CountryIN
Employees293
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.87
Shares Outstanding29,457,249
10 Day Avg. Volume1,280
30 Day Avg. Volume2,199
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.42
Price to Sales (P/S)4.06
P/FCF Ratio-3.45K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Brooks Laboratories Limited Business Overview & Revenue Model
Company Description
Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited w...
How the Company Makes Money
null...
Brooks Laboratories Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
52
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 825.57M | 794.86M | 624.80M | 911.85M | 770.68M |
| Gross Profit | 364.78M | 139.22M | 225.13M | 126.02M | -79.11M | 218.28M |
| EBITDA | 177.76M | 58.22M | 41.73M | -291.68M | -134.50M | 12.52M |
| Net Income | 115.32M | -99.67M | -195.92M | -209.00M | -193.13M | -193.75M |
Balance Sheet | ||||||
| Total Assets | 1.40B | 1.24B | 904.45M | 1.10B | 1.96B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 18.03M | 12.48M | 1.25M | 232.00K | 26.05M | 8.84M |
| Total Debt | 78.33M | 75.83M | 56.42M | 65.12M | 252.59M | 313.85M |
| Total Liabilities | 242.82M | 255.90M | 248.60M | 356.44M | 615.91M | 829.29M |
| Stockholders Equity | 1.16B | 981.04M | 655.85M | 739.53M | 874.90M | 791.48M |
Cash Flow | ||||||
| Free Cash Flow | -3.84M | -971.00K | -101.20M | -149.58M | -650.53M | -11.55M |
| Operating Cash Flow | 3.19M | 17.62M | -96.81M | -144.91M | -374.41M | 44.59M |
| Investing Cash Flow | -1.03M | -460.41M | 1.82M | 4.95M | -249.09M | -51.30M |
| Financing Cash Flow | -2.30M | 441.96M | 96.01M | 114.14M | 640.71M | 11.59M |
Brooks Laboratories Limited Technical Analysis
Neutral
123.65
Price Trends
63.76
Positive
74.74
Negative
106.68
Negative
Market Momentum
2.79
Negative
56.51
Neutral
68.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Neutral. The current price of 123.65 is above the 20-day moving average (MA) of 58.69, above the 50-day MA of 63.76, and above the 200-day MA of 106.68, indicating a neutral trend. The MACD of 2.79 indicates Negative momentum. The RSI at 56.51 is Neutral, neither overbought nor oversold. The STOCH value of 68.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BROOKS.
Brooks Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹3.33B | 36.55 | ― | ― | 26.44% | 31.04% | |
63 Neutral | ₹4.54B | 19.99 | ― | ― | -2.65% | -54.56% | |
55 Neutral | ₹3.37B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
52 Neutral | ₹2.82B | 7.63 | ― | ― | -57.41% | -2188.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹4.11B | 6.87 | ― | 0.66% | -10.36% | -76.23% | |
49 Neutral | ₹1.75B | 10.71 | ― | ― | 15.44% | ― |
* Healthcare Sector Average
IN:BROOKS
Brooks Laboratories Limited
59.45
-73.55
-55.30%
IN:ALBERTDAVD
Albert David Ltd
720.00
-100.51
-12.25%
IN:MEDICAMEQ
Medicamen Biotech Limited
248.15
-176.83
-41.61%
IN:MEDICO
Medico Remedies Ltd.
40.08
-15.41
-27.77%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.58
-9.46
-42.92%
IN:ZIMLAB
Zim Laboratories Ltd.
84.70
-3.30
-3.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.